- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
PDL BioPharma reports Q3 EPS 29c vs street view of 26c. PDL BioPharma (Nasdaq: PDLI) reports Q3 revenue $71.4M vs consensus of $76.48M.
PDL BioPharma lowers FY09 revenue guidance to $310M to $320M. PDL previously had seen FY09 revenue of $319M to $325M versus the street view of $331.96M.